Abstract CT222: Obrixtamig (BI 764532) in patients with relapsed/refractory delta-like ligand 3 (DLL3) high-expressing extrapulmonary neuroendocrine carcinoma (epNEC): trial in progress of the dose expansion part of the Phase II DAREON-5 trial
Year: 2026
Type: conference-abstract
Source: Cancer Research
Institutions: Friedrich-Alexander-Universität Erlangen-Nürnberg, Vall d'Hebron Hospital Universitari, Newcastle University, University of Miami, Sylvester Comprehensive Cancer Center, Boehringer Ingelheim (Germany), Boehringer Ingelheim (China), Boehringer Ingelheim (United States), University of California, San Francisco
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7154684375